This Study Uses the SITS Registry to Find Out When Patients With a Heart Rhythm Disorder (Atrial Fibrillation) Start Treatment With Dabigatran After They Had a Stroke

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1489 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-11-15

Study Completion Date

2019-06-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational study in patients with non-valvular atrial fibrillation (NVAF) presenting to the hospital with a first acute ischemic stroke based on existing data recorded in the SITS International Registry (located in Sweden) by physicians in several European countries, such as Italy, United Kingdom, Czech Republic, Sweden, Germany, Poland, Spain, Finland, Portugal, Slovakia, Denmark, Estonia, Norway Belgium, Hungary, Slovenia, Croatia, Austria, Lithuania, France, Greece, Netherlands, Ireland, Ukraine and Iceland.

The aim of this study is to explore the current real world use of dabigatran for stroke prevention in NVAF patients in the post-stroke setting. Secondary data from eligible European patients registered in the SITS registry will be considered; countries of origin are not known a priori.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Record Of the Use of Dabigatran in Patients With Acute Stroke or TIA

NCT02507856

Brain Ischemia With Non-valvular Atrial Fibrillation Transient Ischemic Attack With Non-valvular Atrial Fibrillation

COMPLETED

Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation

NCT03749057

Cerebral Infarction TIA

COMPLETED PHASE4

Early Administration of Edoxaban After Acute Ischemic Stroke in Patients With Non-valvular Atrial Fibrillation

NCT03433235

Acute Ischemic Stroke

COMPLETED PHASE2

TIMING of Oral Anticoagulant Therapy in Acute Ischemic Stroke With Atrial Fibrillation

NCT02961348

Ischemic Stroke Atrial Fibrillation

COMPLETED NA

Timing of Anticoagulation After Emergency Endovascular Therapy for Acute Ischemic Stroke With Atrial Fibrillation 2

NCT07139314

Ischemic Stroke Atrial Fibrillation

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Acute ischemic stroke

Non-valvular atrial fibrillation patients hospitalized with an acute ischemic stroke

Dabigatran

Intervention Type DRUG

Oral anticoagulant (NOAC) thrombin inhibitor

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dabigatran

Oral anticoagulant (NOAC) thrombin inhibitor

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Pradaxa

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with non-valvular Atrial Fibrillation (NVAF)
* Patients presenting with their first acute ischemic stroke
* ≥18 years of age

Exclusion Criteria

\- Documentation that the patient was enrolled or is planned to be enrolled in an investigational clinical trial at the time of the onset of the index event and for the duration of the data collection

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No